MX2010006867A - Acidos grasos de longitud de cadena media, sales y trigliceridos en combinacion con gemcitabina para el tratamiento de cancer pancreatico. - Google Patents

Acidos grasos de longitud de cadena media, sales y trigliceridos en combinacion con gemcitabina para el tratamiento de cancer pancreatico.

Info

Publication number
MX2010006867A
MX2010006867A MX2010006867A MX2010006867A MX2010006867A MX 2010006867 A MX2010006867 A MX 2010006867A MX 2010006867 A MX2010006867 A MX 2010006867A MX 2010006867 A MX2010006867 A MX 2010006867A MX 2010006867 A MX2010006867 A MX 2010006867A
Authority
MX
Mexico
Prior art keywords
chain length
medium
gemcitabine
triglycerides
salts
Prior art date
Application number
MX2010006867A
Other languages
English (en)
Spanish (es)
Inventor
Lyne Gagnon
Lilianne Geerts
Christopher Penny
Original Assignee
Prometic Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biosciences Inc filed Critical Prometic Biosciences Inc
Publication of MX2010006867A publication Critical patent/MX2010006867A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2010006867A 2007-12-19 2008-12-18 Acidos grasos de longitud de cadena media, sales y trigliceridos en combinacion con gemcitabina para el tratamiento de cancer pancreatico. MX2010006867A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US812907P 2007-12-19 2007-12-19
PCT/CA2008/002190 WO2009076761A1 (en) 2007-12-19 2008-12-18 Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer

Publications (1)

Publication Number Publication Date
MX2010006867A true MX2010006867A (es) 2010-08-31

Family

ID=40795145

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006867A MX2010006867A (es) 2007-12-19 2008-12-18 Acidos grasos de longitud de cadena media, sales y trigliceridos en combinacion con gemcitabina para el tratamiento de cancer pancreatico.

Country Status (15)

Country Link
US (1) US8946190B2 (enExample)
EP (1) EP2231166B1 (enExample)
JP (1) JP5473937B2 (enExample)
KR (1) KR101603351B1 (enExample)
CN (1) CN101903028B (enExample)
AU (1) AU2008338204B2 (enExample)
BR (1) BRPI0821395A2 (enExample)
CA (1) CA2708679C (enExample)
DK (1) DK2231166T3 (enExample)
ES (1) ES2414617T3 (enExample)
MX (1) MX2010006867A (enExample)
NZ (1) NZ586249A (enExample)
PT (1) PT2231166E (enExample)
TW (1) TWI448290B (enExample)
WO (1) WO2009076761A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE029126T2 (en) 2009-05-04 2017-02-28 Prometic Pharma Smt Ltd Substituted aromatic compounds and pharmaceutical uses
EP2632452B1 (en) 2010-10-27 2018-09-26 Prometic Pharma Smt Limited Compounds and compositions for the treatment of cancer
CN102617679B (zh) * 2012-03-13 2014-11-26 北京大学 一种共轭亚油酸与吉西他滨连接的前体药物制备方法及其应用
US9737538B2 (en) 2013-02-12 2017-08-22 Bend Research, Inc. Solid dispersions of low-water solubility actives
EP2956121B1 (en) 2013-02-12 2018-05-30 Bend Research, Inc. Solid dispersions of low-water solubility actives
ES2748562T3 (es) * 2013-02-28 2020-03-17 Basf As Una composición que comprende un compuesto lipídico, un triglicérido y un tensioactivo, y procedimientos de uso de la misma
WO2015116782A1 (en) 2014-01-29 2015-08-06 Board Of Regents, The University Of Texas System Nucleobase analogue derivatives and their applications
MA53188A1 (fr) 2018-10-11 2021-12-31 Basf As Composés aromatiques et leurs utilisations pharmaceutiques

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0462964B1 (en) * 1989-03-13 1998-07-22 Cellegy Pharmaceuticals, Inc. Topical compositions containing aliphatic amines for the treatment of skin diseases
US6340705B1 (en) * 1999-09-10 2002-01-22 Monsanto Technology, Llc Use of α-linolenic acid metabolites for treatment or prevention of cancer
HUP0303817A3 (en) * 2001-04-18 2009-10-28 Prometic Biosciences Medium-chain length fatty acids, glycerides and analogues as neutrophile survival and activation factors and pharmaceutical compositions containing them
WO2003020210A2 (en) * 2001-08-29 2003-03-13 Umd, Inc. Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
US20060012880A1 (en) * 2002-05-02 2006-01-19 Law Benjamin P Optical device with refractive and diffractive properties
DE602004018902D1 (de) 2003-02-07 2009-02-26 Prometic Biosciences Inc Fettsäuren mittlerer kettenlänge, glyceride und analoga als stimulatoren der erythropoiese
ES2264886B1 (es) * 2005-05-12 2008-02-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales.

Also Published As

Publication number Publication date
CN101903028A (zh) 2010-12-01
PT2231166E (pt) 2013-06-17
US20100273731A1 (en) 2010-10-28
KR101603351B1 (ko) 2016-03-14
HK1151244A1 (en) 2012-01-27
TW200934494A (en) 2009-08-16
TWI448290B (zh) 2014-08-11
KR20100101134A (ko) 2010-09-16
JP5473937B2 (ja) 2014-04-16
US8946190B2 (en) 2015-02-03
NZ586249A (en) 2012-05-25
CA2708679A1 (en) 2009-06-25
EP2231166A1 (en) 2010-09-29
JP2011506492A (ja) 2011-03-03
CA2708679C (en) 2016-11-15
BRPI0821395A2 (pt) 2015-06-16
ES2414617T3 (es) 2013-07-22
DK2231166T3 (da) 2013-06-24
CN101903028B (zh) 2013-06-05
EP2231166B1 (en) 2013-03-20
AU2008338204A1 (en) 2009-06-25
EP2231166A4 (en) 2012-02-22
AU2008338204B2 (en) 2015-03-05
WO2009076761A1 (en) 2009-06-25

Similar Documents

Publication Publication Date Title
MX2010006867A (es) Acidos grasos de longitud de cadena media, sales y trigliceridos en combinacion con gemcitabina para el tratamiento de cancer pancreatico.
SG10201400685SA (en) Use Of Eicosapentaenoic Acid Ethyl Ester For Treating Hypertriglyceridemia
BR112014032905A2 (pt) métodos de redução do risco de um evento cardiovascular em um sujeito em terapia com estatina
SG10201908757TA (en) Boronic acids and esters as inhibitors of fatty amide hydrolase
NZ596228A (en) Compositions and methods for the treatment of inflammation
WO2015157559A3 (en) 10',11'-modified saxitoxins useful for the treatment of pain
TN2011000437A1 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
EA200900155A1 (ru) Модуляторы фармакокинетических свойств лекарственных средств
NZ720946A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
EA200701229A1 (ru) Омега-3 жирные кислоты и дислипидемический агент для липидной терапии
NO20092444L (no) Heteroarylamidderivater
MX2009005413A (es) Formas cristalinas del acido zoledronico.
WO2008024433A3 (en) Haloalkyl-substituted pyrimidinone derivatives
TW200505880A (en) Diarylcycloalkyl derivatives, process for their preparation and their use as pharmaceuticals
MX2007002689A (es) 7-azaindoles y su uso como agonistas de ppar.
TW200500349A (en) Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals
TNSN07068A1 (en) Substituted purinyl derivatives with immunomodulator and chemoprotective activity and use alone or with medium - chain length fatty acids or glycerides
BR112014002885A2 (pt) uso de composto orgânico para o tratamento da síndrome de noonan
GEP20125570B (en) Use of indazolemethoxyalkanoic acid for reducing levels of triglycerides, cholesterol and glucose
TW200621732A (en) Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
WO2009038090A1 (ja) セサミン類とアラキドン酸類を含有する組成物
GEP20125680B (en) Carbonic and sulphuric acid salts of 3-(2,2,2-trimethylhydra-zinium) ropionate esters and their use for 3-(2,2,2-rimethyl- hydrazinium) propionate dihydrate preparation
BR112012023063A2 (pt) processo para a preparação de uma composição para raio x, e, composição de diagnóstico para raio x
BRPI0520258A2 (pt) uso de uma composição farmacêutica, método para preparar uma composição farmacêutica, e, uso de uma quantidade eficaz de acetato de eslicarbazepina
WO2007095609A3 (en) Use of benzo-heteroaryl sulfamide derivatives for the treatment of mania and bipolar disorder

Legal Events

Date Code Title Description
FG Grant or registration